Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HK2 | P52789 | 6/20 | 0.53 |
| ▸ | HK1 | P19367 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14520981 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL15966250 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL15966292 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL12371561 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL17210624 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL8930010 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL15966273 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL15590477 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL21753475 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL13012256 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204444-A9 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170016040-A1 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-19 | — | — | US | disclosed |
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2016-12-29 | — | — | US | disclosed |
| US-9290530-B2 | Chemoenzymatic synthesis of heparin and heparan sulfate analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140235575-A1 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | KDM4E 4685/4885LMNA 587/4885CYP2D6 4469/4885 |
| US-20140235575-A1 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | HPSE, ENGASE, GALE | KDM4E 1727/4885LMNA 4542/4885CYP2D6 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.